Sponsor:
Hal Chapman
Code:
NCT05195918
Conditions
Idiopathic Pulmonary Fibrosis
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
EGCG 300 mg + Nintedanib
EGCG 300 mg + Pirfenidone
Placebo 2 capsules + Nintedanib or Pirfenidone
EGCG 600 mg + Nintedanib
EGCG 600 mg + Pirfenidone
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Hal Chapman on 2024-10-18.